CASI Pharmaceuticals (CASI) 10-Q2016 Q1 Quarterly report

Filed: 13 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ASC, began, building, clarification, classification, Codification, commitment, contractual, credit, free, hematopoietic, internationally, minimum, niche, noncurrent, notification, progenitor, provision, QUALITATIVE, QUANTITATIVE, simplified, simplify, stability, statutory, stem, timeline, Topic, unrealized, withholding, yielded

Removed: Academy, acquiring, activity, acute, add, addressing, adult, advancement, agent, amending, America, angiogenic, antiangiogenic, antibody, antiproliferative, augmented, Aurora, avoid, bioavailability, biologic, biological, blood, breast, Captisol, cardiac, cellular, chemotherapy, clinically, colon, combined, comply, compound, conducted, crossover, cycle, deliver, demonstrated, dependent, designation, directly, disease, distinct, diversified, division, dose, dual, employ, enabling, establishing, filed, follicular, formal, formulation, fully, glycol, greater, group, growth, HCC, healthy, hepatocellular, Hospital, human, important, IND, inhibit, inhibition, inhibitor, initiate, integrated, intensity, introduce, investigated, June, key, kinase, leukemia, licensor, limit, liver, locally, longer, lymphoblastic, lymphoma, malignancy, Margaret, marketed, mechanism, meeting, microtubule, monoclonal, myeloid, NHL, North, orally, parallel, path, pathology, Ph, Philadelphia, pivotal, platform, play, potentially, preparing, principle, profile, progressed, propylene, proven, radioisotope, radiolabeled, radiotherapeutic, referred, reflect, reformulate, refractory, regimen, regression, relapse, relapsed, relationship, renal, response, rituximab, safely, sarcoma, selective, selectivity, setting, shorter, single, slower, soft, solid, stage, STS, study, submit, supplement, targeted, technology, therapy, timeframe, tissue, TNBC, toxicity, transplant, tumor, tyrosine, understanding, unique, untreated, VEGFR, volunteer, xenograft, ZEVALIN®therapeutic

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CASI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION BY PRINCIPAL ACCOUNTING OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sara B. Capitelli, as Principal Accounting Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

Date: May 13, 2016		/s/ Sara B. Capitelli
		Sara B. Capitelli Principal Accounting Officer